Compare Medpace Holdings Inc (MEDP) vs Yum China Holdings Inc (YUMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Yum China Holdings Inc — how do they compare? Medpace Holdings Inc trades at $519.93 (market cap $15.08B), while Yum China Holdings Inc trades at $44.39 (market cap $15.09B). The key difference: Medpace Holdings Inc and Yum China Holdings Inc are close in size by market cap, and Yum China Holdings Inc pays a 2.64% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MEDP | YUMC | |
|---|---|---|
Market Cap | $15.08B | $15.09B |
Sector | Technology | Consumer Cyclical |
52-Week High | $620.59 | $57.95 |
52-Week Low | $308.88 | $40.18 |
Enterprise Value | $14.55B | $15.98B |
Dividend Yield | — | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $527.93, down 1.82% today, with a bullish technical outlook supported by moving averages. The company demonstrates strong profitability with 17.19% net margins and 77.25% ROE, though valuation ratios appear elevated with a P/E of 33.83. Recent earnings have consistently beaten expectations, and cash flow is projected to improve significantly in 2026. However, the stock faces headwinds from ongoing class action lawsuits and mixed analyst sentiment with 73.69% hold ratings.
MEDP presents a mixed investment case with strong fundamental performance offset by legal overhangs and premium valuation. The company's consistent earnings beats and projected cash flow improvement support upside potential, but investors should weigh the legal risks and cautious analyst stance against the robust operational metrics.
YUMC trades at $43.92, up 0.11% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $11.80B in 2025, and profitability remains solid with a 7.83% net margin. The acquisition of Pizza Hut China ownership is a strategic move expected to enhance margins.
The outlook is positive with strong analyst support (73.68% buy ratings), but risks include China's macroeconomic headwinds and competitive pressures. Valuation appears reasonable with a P/E of 16.81, suggesting potential for upside if execution continues to exceed expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Yum China Holdings Inc
With almost 10,600 units and USD 9.5 billion in systemwide sales in 2020, Yum China is the largest restaurant chain in China. It generates revenue through its own restaurants and franchise fees. Key concepts include KFC (7,166 units) and Pizza Hut (2,355), but the company's portfolio also includes other brands such as Little Sheep, East Dawning, Taco Bell, Huang Ji Huang, COFFii & Joy, and Lavazza (collectively representing about 985 units). Yum China is a trademark licensee of Yum Brands, paying 3% of total systemwide sales to the company it separated from in October 2016.
Read more on YUMC →
